| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:49 UTC |
|---|
| Update Date | 2022-03-07 02:51:36 UTC |
|---|
| HMDB ID | HMDB0014406 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Anagrelide |
|---|
| Description | Anagrelide is only found in individuals that have used or taken this drug. It is a drug used for the treatment of essential thrombocytosis (ET; essential thrombocythemia). It also has been used in the treatment of chronic myeloid leukemia. [Wikipedia ]The mechanism by which anagrelide reduces blood platelet count is still under investigation. Studies in patients support a hypothesis of dose-related reduction in platelet production resulting from a decrease in megakaryocyte hypermaturation. In blood withdrawn from normal volunteers treated with anagrelide, a disruption was found in the postmitotic phase of megakaryocyte development and a reduction in megakaryocyte size and ploidy. At therapeutic doses, anagrelide does not produce significant changes in white cell counts or coagulation parameters, and may have a small, but clinically insignificant effect on red cell parameters. Anagrelide inhibits cyclic AMP phosphodiesterase III (PDEIII). PDEIII inhibitors can also inhibit platelet aggregation. However, significant inhibition of platelet aggregation is observed only at doses of anagrelide higher than those required to reduce platelet count. |
|---|
| Structure | ClC1=CC=C2N=C3NC(=O)CN3CC2=C1Cl InChI=1S/C10H7Cl2N3O/c11-6-1-2-7-5(9(6)12)3-15-4-8(16)14-10(15)13-7/h1-2H,3-4H2,(H,13,14,16) |
|---|
| Synonyms | | Value | Source |
|---|
| Anagrelida | ChEBI | | Anagrelidum | ChEBI | | BL-4162a | HMDB | | Agrelin | HMDB | | Imidazo(2,1-b)quinazolin-2(3H)-one, 6,7-dichloro-1,5-dihydro-, monohydrochloride | HMDB | | 6,7-Dichloro-1,5-dihydroimidazo(2,1-b)quinazolin-2(3H)-one hydrochloride | HMDB | | Anagrelide hydrochloride | HMDB | | Agrylin | HMDB |
|
|---|
| Chemical Formula | C10H7Cl2N3O |
|---|
| Average Molecular Weight | 256.088 |
|---|
| Monoisotopic Molecular Weight | 254.996617275 |
|---|
| IUPAC Name | 6,7-dichloro-1H,2H,3H,5H-imidazolidino[2,1-b]quinazolin-2-one |
|---|
| Traditional Name | anagrelide |
|---|
| CAS Registry Number | 68475-42-3 |
|---|
| SMILES | ClC1=CC=C2N=C3NC(=O)CN3CC2=C1Cl |
|---|
| InChI Identifier | InChI=1S/C10H7Cl2N3O/c11-6-1-2-7-5(9(6)12)3-15-4-8(16)14-10(15)13-7/h1-2H,3-4H2,(H,13,14,16) |
|---|
| InChI Key | OTBXOEAOVRKTNQ-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as quinazolines. Quinazolines are compounds containing a quinazoline moiety, which is made up of two fused six-member aromatic rings, a benzene ring and a pyrimidine ring. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Diazanaphthalenes |
|---|
| Sub Class | Benzodiazines |
|---|
| Direct Parent | Quinazolines |
|---|
| Alternative Parents | |
|---|
| Substituents | - Quinazoline
- Aryl chloride
- Aryl halide
- Benzenoid
- 3-imidazoline
- Azacycle
- Propargyl-type 1,3-dipolar organic compound
- Organic 1,3-dipolar compound
- Hydrocarbon derivative
- Organooxygen compound
- Organonitrogen compound
- Organochloride
- Organohalogen compound
- Organopnictogen compound
- Organic nitrogen compound
- Organic oxygen compound
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Not Available | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 280 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.28 g/L | Not Available | | LogP | 2.4 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 2.55 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 12.435 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 2.17 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 29.3 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 1775.5 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 387.4 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 137.2 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 254.6 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 107.5 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 437.9 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 612.9 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 92.6 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 972.7 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 406.8 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1278.3 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 298.5 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 320.2 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 486.4 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 186.2 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 89.1 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Anagrelide,1TMS,isomer #1 | C[Si](C)(C)N1C(=O)CN2CC3=C(C=CC(Cl)=C3Cl)N=C21 | 2465.9 | Semi standard non polar | 33892256 | | Anagrelide,1TMS,isomer #1 | C[Si](C)(C)N1C(=O)CN2CC3=C(C=CC(Cl)=C3Cl)N=C21 | 2364.8 | Standard non polar | 33892256 | | Anagrelide,1TMS,isomer #1 | C[Si](C)(C)N1C(=O)CN2CC3=C(C=CC(Cl)=C3Cl)N=C21 | 3637.6 | Standard polar | 33892256 | | Anagrelide,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N1C(=O)CN2CC3=C(C=CC(Cl)=C3Cl)N=C21 | 2641.7 | Semi standard non polar | 33892256 | | Anagrelide,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N1C(=O)CN2CC3=C(C=CC(Cl)=C3Cl)N=C21 | 2589.9 | Standard non polar | 33892256 | | Anagrelide,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N1C(=O)CN2CC3=C(C=CC(Cl)=C3Cl)N=C21 | 3658.5 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Anagrelide GC-MS (Non-derivatized) - 70eV, Positive | splash10-05fu-6790000000-c1e9f41cee65873be06e | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Anagrelide GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental LC-MS/MS | LC-MS/MS Spectrum - Anagrelide , positive-QTOF | splash10-0a4i-0490000000-03df7de701116d2d73fc | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Anagrelide 35V, Negative-QTOF | splash10-0udi-0090000000-e8b3a7f5796e22f53658 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Anagrelide 35V, Positive-QTOF | splash10-002b-0950000000-b8c3541fb23ae10e2269 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Anagrelide 10V, Positive-QTOF | splash10-0a4i-0090000000-d21e45412f17c227abd3 | 2016-06-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Anagrelide 20V, Positive-QTOF | splash10-0a4i-0090000000-102774526a55c3c04a86 | 2016-06-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Anagrelide 40V, Positive-QTOF | splash10-0079-0190000000-875bbead14cce9504096 | 2016-06-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Anagrelide 10V, Negative-QTOF | splash10-0udi-0090000000-3f622f4ee02de52e0106 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Anagrelide 20V, Negative-QTOF | splash10-0udi-0090000000-2d627694d9ac02331074 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Anagrelide 40V, Negative-QTOF | splash10-0159-4290000000-e19fc941d00cc513fbea | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Anagrelide 10V, Positive-QTOF | splash10-0a4i-0090000000-1d28873247abf5ca835e | 2021-09-23 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Anagrelide 20V, Positive-QTOF | splash10-0a4i-0090000000-1d28873247abf5ca835e | 2021-09-23 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Anagrelide 40V, Positive-QTOF | splash10-00bi-0590000000-3c538f3f8332765f4496 | 2021-09-23 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Anagrelide 10V, Negative-QTOF | splash10-0udi-0090000000-e2f0c02f41b77a097d34 | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Anagrelide 20V, Negative-QTOF | splash10-0udi-0090000000-05fc2254e352e0a57c1a | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Anagrelide 40V, Negative-QTOF | splash10-002r-0190000000-779e8518ef504ace69bb | 2021-09-24 | Wishart Lab | View Spectrum |
|
|---|
| General References | - Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR: Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 Jul 7;353(1):33-45. [PubMed:16000354 ]
- Petrides PE: Anagrelide: what was new in 2004 and 2005? Semin Thromb Hemost. 2006 Jun;32(4 Pt 2):399-408. [PubMed:16810615 ]
- Voglova J, Maisnar V, Beranek M, Chrobak L: [Combination of imatinib and anagrelide in treatment of chronic myeloid leukemia in blastic phase]. Vnitr Lek. 2006 Sep;52(9):819-22. [PubMed:17091608 ]
|
|---|